BMY
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$63.06
+0.35%Jul 27, 2026, 13:00 UTC
Theo Ai appointed Sandra Leung, former Executive Vice President and General Counsel of Bristol Myers Squibb, to its Board of Directors.
Source:Jul 13, 2026, 10:59 UTC
The U.S. Food and Drug Administration accepted Bristol Myers Squibb's new drug application for mezigdomide to treat relapsed or refractory multiple myeloma.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 1, 2026, 03:32 UTC
Anthropic announced an in-house drug discovery project targeting neglected diseases, entering the healthtech space.
Source:Jun 30, 2026, 00:00 UTC
Matthew Pauls was appointed as a Class I director of Palvella Therapeutics, Inc.
Jun 17, 2026, 20:16 UTC
Bristol Myers Squibb announced a dividend.
Source:Jun 11, 2026, 11:03 UTC
Takeda Pharmaceutical announced that its experimental once-daily psoriasis pill outperformed Bristol Myers Squibb's Sotyktu in a late-stage head-to-head trial.
Source:Jun 11, 2026, 01:52 UTC
Harbour BioMed appointed Dr. Luisa Salter-Cid as Scientific Advisor.
Source:Jun 4, 2026, 16:55 UTC
Arcus Biosciences and Bristol Myers Squibb have formed a partnership to advance clinical studies of casdatifan combinations for kidney cancer.
Source:Jun 2, 2026, 18:01 UTC
Bristol Myers Squibb announced an update on the label expansion review for Camzyos in the EU.
Source:Jun 2, 2026, 18:01 UTC
Bristol Myers Squibb secured EU approval for Opdivo plus AVD in newly diagnosed advanced classical Hodgkin lymphoma.
Source:Jun 1, 2026, 10:59 UTC
The U.S. FDA accepted for priority review Bristol Myers Squibb's supplemental new drug application for Camzyos to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
Source:Jun 1, 2026, 10:55 UTC
The European Commission approved Bristol Myers Squibb's Opdivo in combination with AVD for previously untreated Stage III or IV classical Hodgkin Lymphoma.
Source:
← PreviousPage 2